Baxter International Inc. (NYSE:BAX) Director John D. Forsyth sold 9,440 shares of the company’s stock in a transaction that occurred on Friday, August 25th. The stock was sold at an average price of $61.76, for a total value of $583,014.40. Following the transaction, the director now directly owns 32,444 shares in the company, valued at $2,003,741.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Baxter International Inc. (NYSE BAX) opened at 61.41 on Wednesday. The stock’s 50 day moving average price is $61.03 and its 200 day moving average price is $56.34. Baxter International Inc. has a 12 month low of $43.13 and a 12 month high of $63.14. The stock has a market capitalization of $33.46 billion, a price-to-earnings ratio of 37.26 and a beta of 0.66.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Wednesday, July 26th. The medical instruments supplier reported $0.63 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.06. The firm had revenue of $2.61 billion during the quarter, compared to analysts’ expectations of $2.59 billion. Baxter International had a return on equity of 14.82% and a net margin of 8.85%. The business’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter last year, the firm earned $0.46 EPS. Analysts expect that Baxter International Inc. will post $2.39 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 2nd. Stockholders of record on Friday, September 1st will be given a $0.16 dividend. The ex-dividend date is Wednesday, August 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 1.04%. Baxter International’s payout ratio is 38.79%.

WARNING: “Baxter International Inc. (BAX) Director John D. Forsyth Sells 9,440 Shares” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/30/baxter-international-inc-bax-director-john-d-forsyth-sells-9440-shares.html.

Several hedge funds have recently bought and sold shares of the company. Baker Ellis Asset Management LLC purchased a new stake in shares of Baxter International during the second quarter worth approximately $109,000. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Baxter International by 6.1% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,533 shares of the medical instruments supplier’s stock worth $131,000 after buying an additional 145 shares in the last quarter. Bronfman E.L. Rothschild L.P. boosted its stake in shares of Baxter International by 3.9% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,776 shares of the medical instruments supplier’s stock worth $144,000 after buying an additional 103 shares in the last quarter. Acrospire Investment Management LLC boosted its stake in shares of Baxter International by 71.3% in the second quarter. Acrospire Investment Management LLC now owns 2,402 shares of the medical instruments supplier’s stock worth $145,000 after buying an additional 1,000 shares in the last quarter. Finally, Trust Co. of Vermont boosted its stake in shares of Baxter International by 8.7% in the first quarter. Trust Co. of Vermont now owns 3,282 shares of the medical instruments supplier’s stock worth $170,000 after buying an additional 262 shares in the last quarter. 83.69% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have recently weighed in on BAX. Cantor Fitzgerald set a $70.00 target price on Baxter International and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Cowen and Company reaffirmed a “market perform” rating and set a $68.00 target price (up from $66.00) on shares of Baxter International in a research report on Thursday, July 27th. Citigroup Inc. began coverage on Baxter International in a research report on Thursday, August 17th. They set a “neutral” rating and a $63.00 target price on the stock. Leerink Swann reaffirmed an “outperform” rating and set a $75.00 target price (up from $67.00) on shares of Baxter International in a research report on Thursday, July 27th. Finally, Zacks Investment Research lowered Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $65.15.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Insider Buying and Selling by Quarter for Baxter International (NYSE:BAX)

Receive News & Stock Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related stocks with our FREE daily email newsletter.